INNT
TOTAL INVALIDATION PROCESSED BY THE IB
21/01/2024
Voltar para busca
Dado oficial do USPTO
KINVITRAR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
21/01/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
03/02/2016
Data de registro
13/09/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/03/2023
Última transação
24/03/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
CH
Examinador
PAQUIN, SAMUEL ROBERT
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; biological preparations and stem cells for pharmaceutical and medical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
28/12/2023
INPC
INVALIDATION PROCESSED
28/12/2023
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
24/11/2023
C71T
CANCELLED SECTION 71
24/03/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
13/09/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
09/06/2017
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
24/02/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/02/2017
FIMP
FINAL DISPOSITION PROCESSED
02/02/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
13/12/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
13/09/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
28/06/2016
PUBO
PUBLISHED FOR OPPOSITION
28/06/2016
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/06/2016
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/06/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/06/2016
RFNP
REFUSAL PROCESSED BY IB
27/05/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
26/05/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/05/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/05/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/05/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/05/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/05/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/05/2016
RFRR
REFUSAL PROCESSED BY MPU
09/05/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/05/2016
CNRT
NON-FINAL ACTION WRITTEN
06/05/2016
DOCK
ASSIGNED TO EXAMINER
04/05/2016
MAFR
APPLICATION FILING RECEIPT MAILED
01/04/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/03/2016
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
25/03/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/03/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KINVITRAR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.